Objective-Expression of the chemokine-like receptor ChemR23 (chemerin receptor 23) has been specifically attributed to plasmacytoid dendritic cells (pDCs) and macrophages and ChemR23 has been suggested to mediate an inflammatory immune response in these cells. Because chemokine receptors are important in perpetuating chronic inflammation, we aimed to establish the role of ChemR23-deficiency on macrophages and pDCs in atherosclerosis. Approach and Results-ChemR23-knockout/knockin mice expressing eGFP (enhanced green fluorescent protein) were generated and after crossing with apolipoprotein E-deficient (Apoe −/− ChemR23 e/e ) animals were fed a western-type diet for 4 and 12 weeks. Apoe −/− ChemR23 e/e mice displayed reduced lesion formation and reduced leukocyte adhesion to the vessel wall after 4 weeks, as well as diminished plaque growth, a decreased number of lesional macrophages with an increased proportion of M2 cells and a less inflammatory lesion composition after 12 weeks of western-type diet feeding. Hematopoietic ChemR23-deficiency similarly reduced atherosclerosis. Additional experiments revealed that ChemR23-deficiency induces an alternatively activated macrophage phenotype, an increased cholesterol efflux and a systemic reduction in pDC frequencies. Consequently, expression of the pDC marker SiglecH in atherosclerotic plaques of Apoe −/− ChemR23 e/e mice was declined. ChemR23-knockout pDCs also exhibited a reduced migratory capacity and decreased CCR (CC-type chemokine receptor)7 expression. Finally, adoptive transfer of sorted wild-type and knockout pDCs into Apoe −/− recipient mice revealed reduced accumulation of ChemR23-deficient pDCs in atherosclerotic lesions. Conclusions-Hematopoietic ChemR23-deficiency increases the proportion of alternatively activated M2 macrophages in atherosclerotic lesions and attenuates pDC homing to lymphatic organs and recruitment to atherosclerotic lesions, which synergistically restricts atherosclerotic plaque formation and progression. Visual Overview-An online visual overview is available for this article. 
A therosclerosis is a western lifestyle associated inflammatory disease of the arterial wall and responsible for ischemic cardiovascular diseases and stroke. Over the last years, a large body of evidence has shown that innate and adaptive immunity play a crucial role in atherosclerotic lesion formation and progression. During early steps of atherogenesis, the subendothelial retention of modified lipids promotes the recruitment of leukocytes into the activated intima. Monocytes, for example, differentiate into macrophages and eventually into lipid-laden foam cells which promote plaque development and vulnerability, while antigen presenting cells such as dendritic cells (DCs) induce an adaptive immune response. 1 In this context also chemokines and their receptors have gained attention and have been implicated in the (patho)physiology of atherosclerosis.
2,3
The chemokine-like receptor ChemR23 (chemerin receptor 23) is a G protein-coupled receptor for the chemoattractant adipokine chemerin and the proresolving molecule, resolvin E1 (RvE1). 4, 5 ChemR23 is expressed by (immature) DCs, among which mainly by unstimulated plasmacytoid dendritic cells (pDCs), and by (inflammatory) macrophages. 6, 7 The ChemR23 ligand chemerin has been identified as a chemotactic factor for pDCs 8, 9 and is secreted as a proprotein that then undergoes several proteolytic cleavages. Different chemerin variants with proinflammatory or anti-inflammatory action can be produced, depending on the class of proteases predominating in the microenvironment. 10 Concomitantly, engagement of ChemR23 has been reported to play a pathophysiological role in more chronic inflammatory diseases, such as lupus, psoriasis, or multiple sclerosis, while it seems to exert beneficial effects in lung inflammation and viral infections. 4 In terms of cardiovascular diseases it was, for example, shown that local chemerin expression within the vascular wall of human plaque specimens 11 and epicardial adipose tissue 12 correlates with the severity of coronary atherosclerosis. Furthermore, chemerin has been implicated in inducing apoptosis of cardiomyocytes, 13 modifying vasoconstriction, 14 and increasing blood pressure, 15 most likely via ChemR23. However, an isoform of chemerin (chemerin15) has been reported to induce alternatively activated M2 macrophage polarization, thereby protecting against myocardial ischemia-reperfusion injury in mice. 16 Another recent study revealed exacerbated atherosclerotic lesion formation in ChemR23-deficient animals, attributing this increase to the lost interaction of ChemR23 with its alternative proresolving ligand RvE1. Supplementation experiments with eicosapentaenoic acid (EPA) as a precursor for the proresolving RvE1 indeed reduced plaque formation in Apoe-deficient mice. However, EPA supplementation was not investigated in ChemR23-deficient mice, leaving the role of ChemR23 in the observed EPA-induced effects on atherosclerosis unanswered. 17 Although several aspects of the ChemR23/chemerin axis with respect to cardiovascular diseases have been investigated, the outcome of ChemR23 expression on pDCs and macrophages, which are the 2 main leukocyte subsets expressing the receptor, has not been addressed in the context of atherosclerosis. Therefore, we generated a ChemR23 reporter mouse model and investigated the role of ChemR23 in atherogenesis and progression in more detail.
Materials and Methods
In adherence to the American Heart Association Journals' implementation of the TOP Guidelines we state: The data that support the findings of this study are available from the corresponding author upon reasonable request.
Mice

ChemR23
e/e mice were generated by Ozgene in C57/Bl6-ES cells. All further breeding was done in C57/Bl6 mice, and all animals used in this study were on C57/Bl6 background. ChemR23
e/e mice were crossed with Apoe −/− mice to generate ChemR23 e/e Apoe −/− mice (all on C57BL/6 background). For atherosclerosis studies, mice were fed a western-type diet (WD) containing 21% fat and 0.15% to 0.2% cholesterol, starting at 8 to 10 weeks of age for 4 or 12 weeks. Animals were sex and age matched also in adherence to the guidelines as described in the ATVB Council Statement. 18 All animal experiments were approved by the local ethical committee (Regierung von Oberbayern, Sachgebiet 54, Germany).
Histology and Immunofluorescence
Atherosclerotic lesion size was assessed by analyzing cryosections of the aortic root by staining for lipid depositions with Oil-Red-O. Aortic arches with the main branch points (brachiocephalic artery, left subclavian artery, and left common carotid artery) were fixed with 4% paraformaldehyde and embedded in paraffin. Lesion size was quantified after Hematoxylin and Eosin-staining.
Intravital Microscopy
Leukocyte adhesion to the carotid artery was analyzed using intravital microscopy, as described.
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Laboratory Blood Parameters and Flow Cytometry
EDTA (ethylendiamintetraacetate)-buffered blood was obtained from Apoe −/− control or ChemR23 e/e Apoe −/− mice and selected blood parameters were determined using an automated blood cell counter. Bone marrow cells were harvested by flushing femurs, spleen, and lymph nodes were mechanically crushed and filtered to obtain single cell suspensions. All cell suspensions were analyzed using a FACS Canto II.
Functional Analysis of pDCs and Aortic Macrophages
pDCs are isolated from bone marrow, and macrophages are isolated from the aortic tree or aorta using FACS sorting. Cells were further processed for polymerase chain reaction, cell culture, or flow cytometric analysis.
Adoptive Transfer
Sorted pDCs are stained using cell tracker proliferation dye eF670. Recipient Apoe −/− mice are fed a WD for 10 weeks. Labeled pDCs are injected intravenous (≈5×10 5 cells/recipient) single cell suspensions of excised aortas are analyzed 24 hours after injection by flow cytometry. Bone marrow was isolated from femurs and tibiae of C57BL/6 control or ChemR23 e/e mice. Cells were cultured for 8 to 9 days to differentiate into bone marrow-derived macrophages. ABCA1/ABCG1 (ATP-binding cassette transporter A1/ATP-binding cassette transporter G1) surface expression was analyzed using flow cytometry. For the cholesterol efflux assay, cultured bone marrow-derived macrophages were replated at 0.5×10 6 cells per well in a 24-well plate and allowed to adhere overnight. Next day the culture medium was replaced by medium containing tritium (3H)-cholesterol (1 µCi/well); and oxLDL (oxidized low-density lipoprotein; 50 µg/mL) for 24 hours. After loading the cells were equilibrated for 2 hours in RPMI (Roswell Park Memorial Institute) medium containing 0.2% bovine serum albumin. Subsequently, cells were incubated for 6 hours with RPMI medium containing 0.2% bovine serum albumin and ApoA1 (15 µg/mL) or HDL (high-density lipoprotein; 50 µg/mL) or received no further treatment. Medium was removed, collected, and the cells were lysed at 37°C with 0.3 mol/L sodium hydroxide solution for 15 minutes. Cell lysate was collected and both, the lysate and the supernatant were transferred to scintillation medium and radioactivity was measured with a scintillator (PerkinElmer). Counts from cellular lysate added with counts from supernatant represent total cholesterol uptake, whereas counts only for supernatant represent cholesterol efflux.
Nonstandard Abbreviations and Acronyms
Statistics
All data are expressed as mean±SEM. Statistics were performed using of GraphPadPrism7. 
Results
ChemR23 Is Expressed on pDCs and Macrophages
To study ChemR23 expression on different cell types and to investigate the deletion of the ChemR23 receptor in an atherosclerotic context, we generated ChemR23-knockout/knockin reporter mice expressing the eGFP (enhanced green fluorescent protein) instead of ChemR23 ( Figure I in the online-only Data Supplement). Subsequently, we bred these mice to apolipoprotein E-deficient (Apoe ) for our atherosclerosis studies. Next, we evaluated ChemR23 (eGFP) expression on different hematopoietic cell types and confirmed its expression on pDCs 8 and macrophages 19 in e/e animals compared with control mice after 12 weeks WD. Combined, these results underline less inflammatory lesion composition and a reduced inflammatory immune response in ChemR23-deficient animals in both early and advanced atherosclerosis. While total cholesterol levels, total leukocyte counts, and body weight did not differ on ChemR23-deficiency, neither after 4 weeks WD (Table I in the online-only Data Supplement) nor after 12 weeks WD (Table II in the online-only Data Supplement), pDC frequencies were significantly reduced in blood, spleen, bone marrow, and lymph nodes of ChemR23-deficient mice in both atherosclerosis studies (Figure 1M and 1N ; Figure IVE in the onlineonly Data Supplement). In contrast, monocyte numbers were not altered after 4 weeks WD, but significantly enhanced in blood while reduced in bone marrow after 12 weeks WD ( Figure 1O ), suggesting increased mobilization of monocytes from the bone marrow to the blood after 12 weeks WD. Nevertheless, chemerin levels were mildly increased after 4 and 12 weeks of WD on ChemR23-deficiency (Figures IIIC and IVF in the online-only Data Supplement). Heterozygous deficiency of ChemR23 did not change lesion size or any other parameters examined (Figure IIID through IIIF and Table III in the online-only Data Supplement).
In summary, despite mild monocytosis in Apoe −/− ChemR23 e/e animals on WD, atherosclerotic lesion formation is reduced, associated with a reduction in lesional macrophages and circulating pDC levels.
Hematopoietic ChemR23 Fuels Lesion Development
Recent studies have suggested that also vascular ECs and smooth muscle cells express ChemR23. 21, 22 Therefore, to examine the role of specifically hematopoietic ChemR23-deficiency in the observed differences in plaque formation, we performed bone marrow transplantations of Apoe −/− ChemR23 e/e bone marrow into Apoe −/− mice with subsequent WD feeding for 6 weeks. Again we observed a significant reduction in atherosclerotic lesion formation (Figure VA through VC in the online-only Data Supplement), diminished lesional macrophage content ( Figure VD in the online-only Data Supplement) and a decline in pDC frequencies in blood, lymph node, and bone marrow (Figure VE in the online-only Data Supplement). Concordant with our findings on total ChemR23-deficiency after 4 and 12 weeks WD, the relative number of monocytes was significantly increased in animals receiving ChemR23-deficient bone marrow (Table IV in the online-only Data Supplement). Thus, the observation that hematopoietic ChemR23-deficiency mimics total ChemR23-knockout underlines the importance of hematopoietic ChemR23 expression in the observed proatherogenic immune response. Supportive of this notion, we could detect in our immunofluorescent analyses of root lesions of ChemR23 e/e reporter mice an eGFP signal in lesional macrophages and pDCs ( Figure VIA and VIB in the online-only Data Supplement). Hence, we conclude that hematopoietic ChemR23 expression fuels lesion development.
ChemR23 Controls Macrophage Polarization in Atherosclerotic Lesions
To unravel mechanisms responsible for reduced lesion formation in ChemR23-deficient animals, we evaluated the macrophage phenotype in more detail, because ChemR23 expression has been suggested to be specific for M1 macrophages at least in vitro 6 and we could detect more CD206+ macrophages in ChemR23-deficient lesions despite a general reduction in lesional macrophages. To this end, we sorted CD11b+F4/80+ macrophages from aortic cell suspensions (arch and thoracal aorta) of Apoe −/− and Apoe −/− ChemR23 e/e animals after 12 weeks WD and found the number of aortic macrophages to be significantly reduced in Apoe −/− ChemR23 e/e animals ( Figure 2A ), paralleling our findings in aortic root lesions ( Figure 1D and 1J) . Gene expression analysis of sorted macrophages furthermore revealed ChemR23-deficiency to cause a significant upregulation of Il10 mRNA expression as a marker of the alternative M2 profile, while the expression of Il6, indicative of a proinflammatory M1 profile, was significantly reduced ( Figure 2B) . A flow cytometric evaluation of the macrophage phenotype in the aortic tree on 12 weeks WD showed again, this time with removal of the adventitia, a diminished total number of macrophages in Apoe −/− ChemR23 e/e mice (data not shown), and when distinguishing between eGFP− and eGFP+ macrophages using flow cytometry, around 50% of aortic macrophages were found to be GFP+ in Apoe −/− ChemR23 e/e mice ( Figure VIC in the online-only Data Supplement). Surface expression of CD301 (M2 marker) and MHCII (major histocompatibility complex II; M1 marker) was significantly upregulated, respectively, downregulated within the GFP+ macrophage compartment compared with GFP− macrophages or the Apoe −/− macrophages in general ( Figure 2C through 2E) . The pronounced M2 phenotype in ChemR23-deficient but GFP+ macrophages points towards an important role of the chemerin/ChemR23 axis in controlling macrophage polarization and induction of an M1 phenotype in (chronic) inflammation, underlining findings from Lin et al 23 showing that chemerin blocks M2 polarization in colitis. To verify these findings independent of Apoe-and ChemR23-deficiency, we injected phosphate-buffered saline, TNF-α (tumor-necrosis-factor alpha), and chemerin into the peritoneal cavity of Bl6 animals and analyzed macrophage numbers as well as CD301 and MHCII surface expression after 4 hours. Here, we revealed an increased number of (recruited) macrophages in the peritoneal cavity of TNF-α and chemerin treated animals and, in contrast to our findings in ChemR23-deficient mice, a significant decrease in the expression of CD301, while MHCII expression was enhanced (Figure VIIA through VIID in the online-only Data Supplement). In addition, chemerin treatment significantly augmented apoptosis (AnnexinV+) in macrophages from wild type but not from ChemR23-deficient animals ( Figure VIIE in the online-only Data Supplement), which may explain the reduced necrotic core size in lesions of Apoe −/− ChemR23 e/e animals ( Figure 1K ). Further, with M1 macrophage polarization reported to reduce cholesterol efflux capacity, 24 we examined the effect of ChemR23-deficiency on cholesterol efflux. As shown in Figure 2F , efflux of 3 H-cholesterol to Apoa1 (apolipoprotein A1) or HDL was significantly enhanced in ChemR23 e/e macrophages compared with control cells, in accordance with an increased M2 polarization on ChemR23-deficiency ( Figure 2D and 2E) . While surface expression of the efflux transporter ABCA1 only increased on ChemR23-deficiency after oxLDL treatment, ABCG1 already increased under baseline conditions in ChemR23-deficient macrophages ( Figure 2G and 2H) . In contrast to the observed effects of ChemR23-deficiency on cholesterol efflux, uptake of Dillabeled LDL (low-density lipoprotein) or Dil-labeled oxLDL was not altered between control and ChemR23-deficient macrophages ( Figure VIIIA in the online-only Data Supplement). Also, the efferocytotic capacity of macrophages was not affected by ChemR23-deficiency ( Figure VIIIB and VIIIC in the online-only Data Supplement).
Taken together, the absence of ChemR23 favors the M2 macrophage phenotype and increases the proportion of alternatively activated macrophages in atherosclerotic lesions, associated with a reduced plaque formation.
ChemR23-Deficiency Decreases CCR7 Expression on pDCs and Limits Their Recruitment to Atherosclerotic Lesions
The involvement of chemokine receptors in the migration of pDCs has been controversially discussed. 25 However, it can be agreed on that ex vivo isolated pDCs (before activation, eg, through TLR7 (toll-like receptor) or TLR9 engagement) express the chemokine receptors CCR (CC-type chemokine receptor)2, CCR5, CCR7, CXCR (CXC-type chemokine receptor)3, CXCR4, and ChemR23, while they only migrate in response to CXCL (CXC-type chemokine ligand)12 (receptor CXCR4) and chemerin (receptor ChemR23). 26, 27 Stimulated pDCs mainly respond to the CCR7 ligands CCL (CC-type chemokine ligand)19 and CCL21, and CCR7 does also essentially contribute to the homing of pDCs to lymph nodes in steady-state and inflammation. 28 However, also ChemR23 has been reported to direct pDC migration to lymphatic organs and, even more important, specifically to sites of inflammation. 9, 27 As pDC frequencies were reduced in lymphatic organs on ChemR23-deficiency in all our atherosclerosis models (Figure 1M and 1N ; Figure VE Next, we examined CXCR4 and CCR7 expression on lymphatic ChemR23-deficient pDCs in comparison to control cells and observed a significant decrease in CCR7 expression on ChemR23 e/e and Apoe −/− ChemR23 e/e on pDCs in steady-state ( Figure 2J and 2K ) and under atherosclerotic conditions ( Figure 2L and 2M) . Expression of CXCR4 did not differ between pDCs from control and knockout animals (data not shown). We further evaluated if ChemR23-deficiency does also impact on other aspects of pDC phenotype such as type I IFN (interferon) production or expression of MHCII and CD86. As depicted in Figure XA Figure 2N ). After 24 hours, the amount of labeled cells in aortic cell suspensions was quantified by flow cytometry, revealing a significant reduction in the number of lesional pDCs in Apoe −/− recipients that received ChemR23-deficient pDCs ( Figure 2O ).
In summary, ChemR23-deficiency reduces CCR7 expression on pDCs, hinders their migration triggered by chemerin and CCL19 as well as their recruitment into atherosclerotic lesions and homing to lymphatic organs. Consequently, pDCmediated proinflammatory immune responses are restricted. 29 In contrast to previous findings, relating exacerbated lesion formation in ChemR23-deficient mice to the interaction of ChemR23 with the alternative proresolving ligand RvE1, the reduction of atherosclerosis observed in our study is likely because of the effects of its canonical ligand chemerin.
Discussion
This study provides evidence that reduced atherosclerosis on ChemR23-deficiency in Apoe −/− mice is accompanied by reduced leukocyte adhesion to inflamed vessels and a less inflammatory plaque phenotype. In addition, we observed an increased abundance of alternatively activated macrophages in atherosclerotic lesions and a systemic reduction in pDC frequencies, as well as a reduced migratory capacity of ChemR23-deficient pDCs to sites of inflammation. We, therefore, conclude that the absence of ChemR23-mediated signaling favors M2 polarization in atherosclerotic lesions and attenuates pDC homing to lymphatic organs and recruitment to sites of inflammation, which synergistically restricts atherosclerotic plaque formation and progression.
Most studies evaluating the impact of the chemerin/ ChemR23 axis on cardiovascular disease have focused on the chemotactic adipokine chemerin. [11] [12] [13] [14] [15] 30 As already outlined in the introduction, different chemerin variants are generated depending on the protease type cleaving the proform. These variants vary in their biological activity and include proinflammatory and anti-inflammatory isoforms, which may outweigh each other depending on the stage of the inflammatory process and the predominant metabolizing enzymes present. 10 For example, chemerin15 has been associated with beneficial effects in mouse myocardial reperfusion injury by inducing alternative macrophage polarization. 16 Others report suppression of M2 polarization by chemerin, 23 and in vitro studies suggest that ChemR23 expression is a marker of inflammatory macrophages. 6 Notably, we see enhanced chemerin levels in plasma ( Figures IIIC, IVD , and VF in the online-only Data Supplement) and bone marrow lavages (data not shown) in all our ChemR23-deficiency models independent of lesion size, suggesting that (pro)-chemerin accumulates because its main receptor is lacking and a negative feedback loop preventing its further generation is missing. However, despite increased levels of chemerin in our ChemR23-deficient mice, pDCs are impaired in numbers as well as in their migratory response to chemerin and homing in lymphatic organs, underlining the important role of the ChemR23/chemerin axis in pDC homing and recruitment. [7] [8] [9] 27, 31 In addition, macrophages in our study reveal an alternative phenotype profile, an increased cholesterol efflux capacity as well as a defective chemerin-induced transmigration on ChemR23-deficiency. This again supports the idea that the ChemR23/chemerin axis plays a central role in shaping macrophage-mediated immune responses, 6, 19 and, taking into account previous findings on chemerin15 inducing alternative macrophage polarization, 16 the ChemR23-mediated response in macrophages may be proinflammatory or anti-inflammatory depending on the main protease processing prochemerin. However, in chronic inflammation such as atherosclerosis, inflammation resolution is disturbed because of a reduced or imbalanced presence of proresolving mediators. 32, 33 The latter may also apply to the relative abundance of proinflammatory versus anti-inflammatory chemerin variants because of an altered availability of prochemerin-processing proteases under chronic inflammatory conditions. It would be helpful to quantify the individual variants in inflammatory settings; however, this is difficult to achieve because of the small differences in amino acid sequence and structure.
To our knowledge only one other, recent study has addressed the role of ChemR23-deficiency in atherosclerosis. First, Laguna-Fernandez et al 17 show that supplementation of the RvE1-precursor EPA significantly attenuated atherosclerotic lesion growth induced by WD in Apoe −/− mice and altered lipoprotein metabolism with a dramatic (50%) reduction in total cholesterol levels. In a complementary approach, they also knockedout ChemR23 in Apoe −/− mice and evaluated atherosclerosis after WD feeding, though in a rather limited number of animals. 17 Distinct from their supplementation studies, no changes in total cholesterol levels were observed on ChemR23-deficiency, in accordance with our study. However, surprisingly and in contrast to our findings, Laguna-Fernandez et al 17 ) and the cholesterol content of the diet (≈0.15%) are comparable between this and our study, it remains elusive why the reported results differ in opposite directions. As one potential explanation, plaques in our study were much more advanced, showing a plaque area of ≈10% and 37% of the aortic root surface after 4 and 12 weeks WD, respectively, compared with ≈6% and 13% of aortic root area after 8 and 12 weeks WD, respectively, in the study of Laguna-Fernandez et al. 17 Of note, aortic root lesions in the latter study were only reduced by ChemR23-knockout after 8 but not 12 weeks of WD, with accompanying root lesion sizes (≈6%) below those investigated in our study. This suggests that the atheroprogressive effect of ChemR23-deficiency observed by Laguna-Fernandez et al 17 may only be observed in early stages of atherosclerosis, whereas in stages of larger lesion areas and thus higher inflammatory settings (as in our study already after 4 weeks WD compared with the study of Laguna-Fernandez et al 17 ), a protective effect of ChemR23-deficiency may take the overhand. Differential, stage-dependent effects on atherosclerosis have been observed before. 34 As a potential underlying mechanism, the overall outcome of ChemR23-deficiency may be predominated by differential cellular effects depending on the stage of atherosclerosis. As such, the effects of ChemR23-deficiency on hematopoietic cells may overrule in advanced atherosclerosis (as in our study), whereas effects on vascular cells may predominate in earlier stages of atherosclerosis. Our immunohistochemical analyses of ChemR23 in atherosclerotic root lesions indeed also revealed ChemR23 expression in ECs and smooth muscle cells (data not shown), in line with previous reports. 21, 22 As chemerin was shown to act anti-inflammatory on ECs, 22 and ECs play an important atheroprotective role already in early stages of atherosclerosis, the absence of anti-inflammatory chemerin/ChemR23 signaling in ECs may be important mostly in early atherosclerosis and contribute to the observed plaque increase in ChemR23-deficient mice in the early atherosclerosis study of Laguna-Fernandez et al. 17 When atherosclerosis progresses, the proinflammatory effects of chemerin/ChemR23 signaling on macrophages and pDCs may gradually increase in importance and eventually take the overhand, resulting in reduced atherosclerosis on ChemR23-deficiency, as observed in our study of more advanced atherosclerosis. A follow-up study addressing the role of ChemR23 specifically in nonhematopoietic cells is warranted to shed more light on cell type-specific effects of ChemR23 in different stages of atherosclerosis.
Further, in the case of ChemR23, a stage-dependent effect of knockout on atherosclerosis might be triggered by an altered balance of its multiple ligands, either being RvE1 or different chemerin variants, in the course of increasing atherosclerosis and inflammation, as discussed above. In this context, Laguna-Fernandez et al 17 unfortunately do not provide a proof of principle study supplying Apoe −/− ChemR23 e/e mice with the RvE1-precursor EPA to investigate whether the observed protective effects of EPA are mediated by ChemR23 or instead by another receptor of RvE1 (eg, BLT1) 35 or are rather related to the high changes in total cholesterol levels
